Our medical, nursing and allied health clinicians are increasingly involved in research to improve the care of our patients. This is reflected in the breadth of our research publications.
Recent advances and future challenges in Gaucher disease
Zimran, A; Szer, J
(2018), Blood Cells Mol. Dis., 9-13
Preface to the special issue on Gaucher disease 2017
Zimran, A; Szer, J
(2018), Blood Cells Mol. Dis., 1-2
Rapid intravenous infusion of velaglucerase-alfa in adults with type 1 Gaucher disease
Zimran, A; Revel-Vilk, S; Becker-Cohen, M; Chicco, G; Arbel, N; Rolfs, A; Szer, J
(2018), Am. J. Hematol., E246-E248
DOI: 10.1002/ajh.25205
Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy
Zimran, A; Goldblatt, J; Szer, J
(2018), Blood Cells Mol. Dis., 14-16
Addressing Ethical and Procedural Principles for Unrelated Allogeneic Hematopoietic Progenitor Cell Donation in a Changing Medical Environment
van Walraven, SM; Egeland, T; Borri, V; Faveri, GND; Rall, G; Szer, J
(2018), Biol. Blood Marrow Transplant., 887-894
Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies
Tiong, IS; Reynolds, J; Bradstock, KF; Seymour, JF; Wei, AH
(2018), Blood Cancer J.
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
Teh, TC; Nguyen, NY; Moujalled, DM; Segal, D; Pomilio, G; Rijal, S; Jabbour, A; Cummins, K; Lackovic, K; Blombery, P; Thompson, E; Ekert, PG; Lessene, G; Glaser, SP; Huang, DCS; Roberts, AW; Guthridge, MA; Wei, AH
(2018), Leukemia, 303-312
DOI: 10.1038/leu.2017.243
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia
Tam, CS; LeBlond, V; Novotny, W; Owen, RG; Tedeschi, A; Atwal, S; Cohen, A; Huang, J; Buske, C
(2018), Future Oncol., 2229-2237
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Tam, CS; Anderson, MA; Pott, C; Agarwal, R; Handunnetti, S; Hicks, RJ; Burbury, K; Turner, G; Di Iulio, J; Bressel, M; Westerman, D; Lade, S; Dreyling, M; Dawson, SJ; Dawson, MA; Seymour, JF; Roberts, AW
(2018), N. Engl. J. Med., 1211-1223
Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas
Stathis, A; Iasonos, A; Seymour, JF; Thieblemont, C; Ribrag, V; Zucca, E; Younes, A
(2018), Clin. Cancer Res., 2993-2998
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Seymour, JF; Kipps, TJ; Eichhorst, B; Hillmen, P; D'Rozario, J; Assouline, S; Owen, C; Gerecitano, J; Robak, T; De la Serna, J; Jaeger, U; Cartron, G; Montillo, M; Humerickhouse, R; Punnoose, EA; Li, Y; Boyer, M; Humphrey, K; Mobasher, M; Kater, AP
(2018), N. Engl. J. Med., 1107-1120
Selected state of the art research in internal medicine, 2017
Scott, I; McGavigan, A; Ferson, M; Woolley, I; Burt, MG; Russell, A; Bridgman, P; Ting, J; Blacker, D; Bonomo, Y; Martin, J; Szer, J
(2018), Intern. Med. J., 619-623
DOI: 10.1111/imj.13820
MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML
Sanders, MA; Chew, E; Flensburg, C; Zeilemaker, A; Miller, SE; al Hinai, AS; Bajel, A; Luiken, B; Rijken, M; McIennan, T; Hoogenboezem, RM; Kavelaars, FG; Frohling, S; Blewitt, ME; Bindels, EM; Alexander, WS; Lowenberg, B; Roberts, AW; Valk, PJM; Majewski, IJ
(2018), Blood, 1526-1534
Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies
Roth, A; Rottinghaus, ST; Hill, A; Bachman, ES; Kim, JS; Schrezenmeier, H; Terriou, L; Urbano-Ispizua, A; Wells, RA; Jang, JH; Kulasekararaj, AG; Szer, J; Aguzzi, R; Damokosh, AI; Shafner, L; Lee, JW
(2018), Blood Adv., 2176-2185
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
Ross, DM; Pagani, IS; Shanmuganathan, N; Kok, CH; Seymour, JF; Mills, AK; Filshie, RJ; Arthur, CK; Dang, P; Saunders, VA; Braley, J; Yong, AS; Yeung, DT; White, DL; Grigg, AP; Schwarer, AP; Branford, S; Hughes, TP
(2018), Leukemia, 2572-2579
Management of Pregnancy in Women With Chronic Myeloid Leukemia
Ross, DM; Burbury, KL; Grigg, AP; Hughes, TP; Seymour, JF
(2018), J. Clin. Oncol., 2657-+
How we manage Gaucher Disease in the era of choices
Revel-Vilk, S; Szer, J; Mehta, A; Zimran, A
(2018), Br. J. Haematol., 467-480
DOI: 10.1111/bjh.15402
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma
Radivoyevitch, T; Dean, RM; Shaw, BE; Brazauskas, R; Tecca, HR; Molenaar, RJ; Battiwalla, M; Savani, BN; Flowers, MED; Cooke, KR; Hamilton, BK; Kalaycio, M; Maciejewski, JP; Ahmed, I; Akpek, G; Bajel, A; Buchbinder, D; Cahn, JY; D'Souza, A; Daly, A; DeFilipp, Z; Ganguly, S; Hamadani, M; Hayashi, RJ; Hematti, P; Inamoto, Y; Khera, N; Kindwall-Keller, T; Landau, H; Lazarus, H; Majhail, NS; Marks, DI; Olsson, RF; Seo, S; Steinberg, A; William, BM; Wirk, B; Yared, JA; Aljurf, M; Abidi, MH; Allewelt, H; Beitinjaneh, A; Cook, R; Cornell, RF; Fay, JW; Hale, G; Chakrabarty, JH; Jodele, S; Kasow, KA; Mahindra, A; Malone, AK; Popat, U; Rizzo, JD; Schouten, HC; Warwick, AB; Wood, WA; Sekeres, MA; Litzow, MR; Gale, RP; Hashmi, SK
(2018), Leuk. Res., 130-136
Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabine
Prabahran, A; Tacey, M; Fleming, S; Wei, A; Tate, C; Marlton, P; Wight, J; Grigg, A; Tuckfield, A; Szer, J; Ritchie, D; Chee, L
(2018), Eur. J. Haematol., 174-184
DOI: 10.1111/ejh.13089
Hemoglobinopathies in the Fetal Position
Pasricha, SR; Drakesmith, H
(2018), N. Engl. J. Med., 1675-1677
Reducing anaemia in low income countries: control of infection is essential
Pasricha, SR; Armitage, AE; Prentice, AM; Drakesmith, H
(2018), BMJ-British Medical Journal
DOI: 10.1136/bmj.k3165
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
Pardanani, A; Gotlib, J; Roberts, AW; Wadleigh, M; Sirhan, S; Kawashima, J; Maltzman, JA; Shao, L; Gupta, V; Tefferi, A
(2018), Leukemia, 1034-1037
DOI: 10.1038/leu.2017.330
Activity and Capacity Profile of Transplant Physicians and Centers in Australia and New Zealand
Nivison-Smith, I; Milliken, S; Dodds, AJ; Gottlieb, D; Kwan, J; Ma, DDF; Shaw, PJ; Tran, S; Wilcox, L; Szer, J
(2018), Biol. Blood Marrow Transplant., 169-174
Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse
Lim, ABM; Curley, C; Fong, CY; Bilmon, I; Beligaswatte, A; Purtill, D; Getta, B; Johnston, AM; Armytage, T; Collins, M; Mason, K; Fielding, K; Greenwood, M; Gibson, J; Hertzberg, M; Wright, M; Lewis, I; Moore, J; Curtis, D; Szer, J; Kennedy, G; Ritchie, D
(2018), Intern. Med. J., 276-285
DOI: 10.1111/imj.13522
Classifying the additional morbidities of Gaucher disease
Langeveld, M; Elstein, D; Szer, J; Hollak, CEM; Zimran, A
(2018), Blood Cells Mol. Dis., 209-+
Intraobserver and interobserver variability of the bone marrow burden (BMB) score for the assessment of disease severity in Gaucher disease. Possible impact of reporting experience
Lai, JKC; Robertson, PL; Goh, C; Szer, J
(2018), Blood Cells Mol. Dis., 121-125
Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation
Kelly, DL; Buchbinder, D; Duarte, RF; Auletta, JJ; Bhatt, N; Byrne, M; DeFilipp, Z; Gabriel, M; Mahindra, A; Norkin, M; Schoemans, H; Shah, AJ; Ahmed, I; Atsuta, Y; Basak, GW; Beattie, S; Bhella, S; Bredeson, C; Bunin, N; Dalal, J; Daly, A; Gajewski, J; Gale, RP; Galvin, J; Hamadani, M; Hayashi, RJ; Adekola, K; Law, J; Lee, CJ; Liesveld, J; Malone, AK; Nagler, A; Naik, S; Nishihori, T; Parsons, SK; Scherwath, A; Schofield, HL; Soiffer, R; Szer, J; Twist, I; Warwick, A; Wirk, BM; Yi, J; Battiwalla, M; Flowers, ME; Savani, B; Shaw, BE
(2018), Biol. Blood Marrow Transplant., 228-241
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial
Kantarjian, HM; Fenaux, P; Sekeres, MA; Szer, J; Platzbecker, U; Kuendgen, A; Gaidano, G; Wiktor-Jedrzejczak, W; Carpenter, N; Mehta, B; Franklin, J; Giagounidis, A
(2018), Lancet Haematol., E117-E126
Changing role of bone marrow examination in the diagnosis of hematological malignancies
Juneja, S; Westerman, D
(2018), Leuk. Lymphoma, 2018-2020